S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Hot Potato: Lamb Weston Stock Confirms a Top 
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
NASDAQ:OPNT

Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News

$11.07
-0.53 (-4.57%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.07
$11.77
50-Day Range
$9.52
$13.48
52-Week Range
$7.34
$37.71
Volume
23,111 shs
Average Volume
14,871 shs
Market Capitalization
$57.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Opiant Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
279.4% Upside
$42.00 Price Target
Short Interest
Healthy
0.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$60,254 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.40) to ($1.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

230th out of 1,072 stocks

Pharmaceutical Preparations Industry

100th out of 534 stocks

OPNT stock logo

About Opiant Pharmaceuticals (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Opiant Pharmaceuticals Posts Wider Q1 Loss
Opiant Pharmaceuticals: Q4 Earnings Insights
See More Headlines
Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Company Calendar

Last Earnings
8/11/2022
Today
10/06/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$42.00
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+279.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$3.01 million
Pretax Margin
-51.16%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Cash Flow
$0.80 per share
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$57.12 million
Optionable
Not Optionable
Beta
0.57

Social Links


Key Executives

  • Dr. Roger  Crystal M.D.Dr. Roger Crystal M.D. (Age 46)
    Pres, CEO & Director
    Comp: $1.01M
  • Mr. David D. O'Toole (Age 63)
    Chief Financial Officer
    Comp: $624.74k
  • Dr. Phillip Skolnick D.Sc. (hon) (Age 75)
    Ph.D., Chief Scientific Officer
    Comp: $638.17k
  • Mr. Ben Atkins
    VP of Communications & Investor Relations
  • Mr. Brian Gorman
    EVP Corp. Devel. & Gen. Counsel
  • Dr. Mark Heath Ellison Ph.D.
    Chief Devel. Officer
  • Mr. Matthew R. RuthMr. Matthew R. Ruth (Age 52)
    Chief Commercial Officer













OPNT Stock - Frequently Asked Questions

Should I buy or sell Opiant Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPNT shares.
View OPNT analyst ratings
or view top-rated stocks.

What is Opiant Pharmaceuticals' stock price forecast for 2022?

2 analysts have issued 12 month price objectives for Opiant Pharmaceuticals' stock. Their OPNT share price forecasts range from $42.00 to $42.00. On average, they predict the company's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 279.4% from the stock's current price.
View analysts price targets for OPNT
or view top-rated stocks among Wall Street analysts.

How have OPNT shares performed in 2022?

Opiant Pharmaceuticals' stock was trading at $33.63 at the start of the year. Since then, OPNT shares have decreased by 67.1% and is now trading at $11.07.
View the best growth stocks for 2022 here
.

When is Opiant Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our OPNT earnings forecast
.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, August, 11th. The technology company reported ($2.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.29) by $1.02. The technology company earned $3.89 million during the quarter, compared to analysts' expectations of $5.37 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 51.18%.

What other stocks do shareholders of Opiant Pharmaceuticals own?
What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $11.07.

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $57.12 million and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($4.07) on an earnings per share basis.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105.

This page (NASDAQ:OPNT) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.